Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and out...

Full description

Bibliographic Details
Main Authors: Sarah Gooding, I-Jun Lau, Mimi Sheikh, Pamela Roberts, Julia Wong, Emmy Dickens, Ash Bullement, Jamie Elvidge, Dawn Lee, Karthik Ramasamy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4569348?pdf=render

Internet

http://europepmc.org/articles/PMC4569348?pdf=render

Similar Items